These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 8782017)

  • 41. Effects of guggulsterones-containing thermogenic complex on elvitegravir plasma concentrations: a case report.
    Cattaneo D; Ridolfo A; Baldelli S; Gervasoni C
    Eur J Clin Pharmacol; 2019 Aug; 75(8):1177-1178. PubMed ID: 30982083
    [No Abstract]   [Full Text] [Related]  

  • 42. FP 21399.
    Drugs R D; 1999 Nov; 2(5):343-4. PubMed ID: 10728476
    [No Abstract]   [Full Text] [Related]  

  • 43. Vancouver: optimism, but at a cost.
    Churchill D; Pym A; Coker R
    Int J STD AIDS; 1996 Oct; 7(6):385-7. PubMed ID: 8940665
    [No Abstract]   [Full Text] [Related]  

  • 44. In vitro evaluation of experimental agents for anti-HIV activity.
    Richman DD; Johnson VA; Mayers DM; Shirasaka T; O'Brien MC; Mitsuya H
    Curr Protoc Immunol; 2001 May; Chapter 12():Unit 12.9. PubMed ID: 18432713
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Defining success with antiretroviral therapy.
    Schacker TW
    JAMA Intern Med; 2015 Jan; 175(1):99-100. PubMed ID: 25419970
    [No Abstract]   [Full Text] [Related]  

  • 46. Editorial: HIV and Antiretroviral Drugs: Current Status and New Challenges.
    Nikolopoulos G; Bonovas S
    Curr Pharm Des; 2017; 23(18):2551. PubMed ID: 28425865
    [No Abstract]   [Full Text] [Related]  

  • 47. Consensus statement. Scientific Advisory Committee on Surrogate Markers of HIV.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S114-6. PubMed ID: 7552508
    [No Abstract]   [Full Text] [Related]  

  • 48. Will CURE trials introduce an uncomfortable revolution in the field of HIV research?
    Protière C; Préau M; Doumergue M; Mora M; Lambotte O; Spire B; Suzan-Monti M
    HIV Clin Trials; 2017 Jul; 18(4):174-175. PubMed ID: 28587569
    [No Abstract]   [Full Text] [Related]  

  • 49. HIV viral load markers in clinical practice.
    Saag MS; Holodniy M; Kuritzkes DR; O'Brien WA; Coombs R; Poscher ME; Jacobsen DM; Shaw GM; Richman DD; Volberding PA
    Nat Med; 1996 Jun; 2(6):625-9. PubMed ID: 8640545
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-HIV therapy with antisense oligonucleotides and ribozymes: realistic approaches or expensive myths?
    Akhtar S; Rossi JJ
    J Antimicrob Chemother; 1996 Aug; 38(2):159-65. PubMed ID: 8877530
    [No Abstract]   [Full Text] [Related]  

  • 51. The antiproliferative agents trans-bis(resorcylaldoximato)copper(II) and trans-bis(2,3,4-trihydroxybenzaldoximato)copper(II) and cytopathic effects of HIV.
    Elo H
    Z Naturforsch C J Biosci; 2004; 59(7-8):609-11. PubMed ID: 15813388
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Editorial: Extra-Cellular Factors as New Anti-HIV Therapeutic Target.
    Federico M
    Curr Drug Targets; 2016; 17(1):3. PubMed ID: 26687603
    [No Abstract]   [Full Text] [Related]  

  • 53. [III. IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro 24-27 July 2005. Part 2].
    Marcus U
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Mar; 49(3):310-7. PubMed ID: 16465519
    [No Abstract]   [Full Text] [Related]  

  • 54. HIV-1 and HAART: a time to cure, a time to kill.
    Saag MS; Kilby JM
    Nat Med; 1999 Jun; 5(6):609-11. PubMed ID: 10371490
    [No Abstract]   [Full Text] [Related]  

  • 55. [Viral dynamics in the course of HIV-1 infection: pathogenetic features and new therapeutic prospects].
    Marcello A; Giacca M
    Pathologica; 2000 Aug; 92(4):291-3. PubMed ID: 11029891
    [No Abstract]   [Full Text] [Related]  

  • 56. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy.
    Huttner AC; Kaufmann GR; Battegay M; Weber R; Opravil M
    AIDS; 2007 May; 21(8):939-46. PubMed ID: 17457087
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Surrogate endpoints in clinical studies exemplified by HIV infection].
    Furrer H
    Schweiz Med Wochenschr; 1998 Jul; 128(27-28):1079-88. PubMed ID: 9691341
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: risk without reward.
    Abbas UL; Mellors JW
    Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13377-8. PubMed ID: 12370421
    [No Abstract]   [Full Text] [Related]  

  • 59. Effect of antiretroviral therapy on plasma HIV RNA.
    Saag MS
    J Biol Regul Homeost Agents; 1995; 9(3):105-6. PubMed ID: 8782017
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.